



B E A T
T H E R A P E U T I C S

REDEFINING CANCER
TREATMENT

Mission

To develop effective therapeutic options for patients facing hard-to-treat cancers.





1.7 Million

new cancer cases/year

HARD TO TREAT CANCERS

7/10 DEATHS


(5-YEAR SURVIVAL)



Pancreatic Cancer



Ovarian Cancer



**Triple Negative
Breast Cancer**



**Castrate-resistant
Prostate Cancer**

BBIT20

A FIRST-IN-CLASS
ANTICANCER
THERAPEUTIC



PATENTED

WO 2022/053998 A1

Competitive advantages



BBIT20
 **BEAT**
 THERAPEUTICS

CHEMOTHERAPY
 Ex: Gemcitabine 


TARGETED THERAPIES
 < 30% patients
 Ex: PARPi 

	BBIT20	CHEMOTHERAPY	TARGETED THERAPIES
Tumor reduction	4-20x	1x	1x
Cell death induction	✓	✗	✗
Required Doses/ Side-effects	Low	High	High
Toxicity/side-effects	None-Low	High	High
Efficient in resistant cancer cells	✓	✗	✗
Resistance induction	None	High	High
Regulatory approval	✗	✓	✓

BBIT20
 The ONLY
 BRCA1/BARD1
 cancer targeted
 therapy

Raimundo L. et al., BBIT20 inhibits homologous DNA repair with disruption of the BRCA1–BARD1 interaction. British Journal of Pharmacology, 2021


Annual Global Market



163MM€


1.7 M Patients

Pancreatic, Ovarian, Prostate, TNBC



47MM€

Pancreatic Cancer



26MM€

Pancreatic Cancer Advanced Stages
(Stage III, Stage IV)

Clinical Priority - Pancreatic Cancer

Proxy: PARP inhibitors (8.000€/avg month)

Business Model

B2B

M&A w/ Pharmaceutical companies



PROXY deals


\$625 million	\$65 million	\$125 million



Roadmap

MILESTONES

M0
Incorporation & IP
Licencing to New
Company



400.000 €
Seed

SERIES A Round
&
Non-dilutive funding
(4M€)

INVESTMENT NEEDS
4.4 M€

Fundraising & Partners



EXIT


Fundraising & Awards



Key Partnerships & Network



R&D



Clinical




Patients Association



Team



Co-founders



Hugo Prazeres
CEO

Biomedicine PhD & MBA

+ 15 years' experience CEO,
IP management & technology
transfer.



Ângela Carvalho
COO

Biomedical Engineer, PhD


+ 5 years' experience
management and leadership.
Tech transfer & entrepreneurship.



Lucília Saraiva
CSO

Pharmacology, PharmD, PhD

Expert drug discovery,
Cancer pharmacology and cancer
pathways.



Mª José Umbelino
Head of Manufacture

Chemistry, PharmD, PhD

Expert on drug discovery from
natural compounds & Chemical
synthesis.




Lúcio Lara Santos
Medical Affairs

Oncologist, MD, PhD, IPO-Porto

Expertise on translational
research & Clinical Trials.
Surgeon & Researcher.

R&D & Manufacturing




Ana Catarina Matos
MSc in Pharmacy

Juliana Calheiros
MSc in Biochemistry

Rita Silva
BSc in Pharmacy

Filipa Barbosa
MSc in Pharmacy


Business & Product Development



Tomás Pinheiro
MSc Student

Pedro Dinis
MSc Student

Clinical Advisory Board



Mª Fátima Vaz
Oncologist, MD, PhD
IPO-Lisbon

Stefano Indracollo
Oncologist, MD, PhD
Istituto Oncologico, U.
Padova, Italy




BEAT

THERAPEUTICS

BEATING hard on cancer

 [beat-therapeutics](#)

 beat.therapeutics@gmail.com

 +351 960 141 361

